Skip to main content
Clinical Trials/NCT06479096
NCT06479096
Completed
Not Applicable

Four-Week Oral Malodor and Clinical Safety for a Concentrated Cosmetic Mouthwash

Johnson & Johnson Consumer and Personal Products Worldwide1 site in 1 country166 target enrollmentJuly 15, 2024
ConditionsOral Malodor

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Oral Malodor
Sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Enrollment
166
Locations
1
Primary Endpoint
Mean malodor intensity assessed at 120 minutes after product use
Status
Completed
Last Updated
last year

Overview

Brief Summary

The objective of this study is to evaluate the safety of the concentrated mouthwash prototypes, and to evaluate the efficacy of the concentrated mouthwash prototypes in the control of oral malodor compared to a comparator mouthwash and a negative control.

Registry
clinicaltrials.gov
Start Date
July 15, 2024
End Date
September 12, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Able to comprehend and follow the requirements and restrictions of the clinical trial (including willingness to use the assigned study products per instructions, availability on scheduled visit dates and likeliness of completing the clinical trial) based upon research site personnel's assessment;
  • Evidence of a personally signed and dated informed consent document indicating the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial;
  • Able to read and understand the local language (subject is capable of reading the documents);
  • Adequate oral hygiene (i.e., brush teeth daily and exhibit no signs of oral neglect);
  • Adults, 18 years of age and older, in good general and oral health without any known allergy to commercial dental products or cosmetics;
  • Negative pregnancy urine tests (females of child-bearing potential only);
  • For females: Postmenopausal state (i.e. at least 1 year without menses without an alternative medical condition prior to the first study IP administration) or premenopausal/perimenopausal state with an effective means of contraception.
  • For males: No pregnant or lactating spouse or partner at screening and willingness to utilize an acceptable form of birth control with spouse or any potential partner during the study and for 30 days thereafter.
  • Females of childbearing potential must be using a medically acceptable method of birth control for at least one month prior to Visit 1 and agree to continue using this method during their participation in the clinical trial. Medically acceptable forms of birth control that may be used by the subject and/or his/her partner include:
  • Double barrier method (condoms, diaphragm or cervical cap with spermicide),

Exclusion Criteria

  • Diagnosed with Xerostomia;
  • Suspected alcohol or substance abuse at the discretion of the Investigator (e.g., amphetamines, benzodiazepines, cocaine, marijuana, opiates);
  • Known sensitivity, allergy or contraindications to any investigational product ingredient, oral care products and auxiliary supplies provided for the study;
  • Self-reported smokeless tobacco user including snuff, chewing tobacco, vaping and e-cigarette usage;
  • Females who are pregnant, planning to become pregnant or breastfeeding during the study;
  • Subjects who were previously screened and determined to be ineligible for the study (unless subject previously screen failed for the OralChroma GC and/or organoleptic criteria;
  • Participation in any clinical study investigation within 30 days of Screening visit (Visit 1);
  • Planned surgery during the trial period, 6 months prior to clinic visit 1 or 30 days after the end of study period;
  • Has a compromised immune system;
  • Has any acute or chronic, medical or psychiatric conditions) that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the medically qualified investigator, would make the subject inappropriate for entry in this study;

Outcomes

Primary Outcomes

Mean malodor intensity assessed at 120 minutes after product use

Time Frame: After 120 minutes of product use

Mean malodor intensity will be independently assessed by three odor trained judges 120 minutes after product use on Day 0 using the following scale: 0 = No appreciable odor, 1 = Barely noticeable odor, 2 = Slight but clearly noticeable odor, 3 = Moderate odor, 4 = Strong odor, 5 = Extremely foul odor

Mean malodor intensity assessed at 240 minutes after product use

Time Frame: After 240 minutes of product use

Mean malodor intensity will be independently assessed by three odor trained judges 240 minutes after product use on Day 0 using the following scale: 0 = No appreciable odor, 1 = Barely noticeable odor, 2 = Slight but clearly noticeable odor, 3 = Moderate odor, 4 = Strong odor, 5 = Extremely foul odor

Mean malodor intensity assessed at 60 minutes after product use

Time Frame: After 60 minutes of product use

Mean malodor intensity will be independently assessed by three odor trained judges 60 minutes after product use on Day 0 using the following scale: 0 = No appreciable odor, 1 = Barely noticeable odor, 2 = Slight but clearly noticeable odor, 3 = Moderate odor, 4 = Strong odor, 5 = Extremely foul odor

Mean malodor intensity assessed at 180 minutes after product use

Time Frame: After 180 minutes of product use

Mean malodor intensity will be independently assessed by three odor trained judges 180 minutes after product use on Day 0 using the following scale: 0 = No appreciable odor, 1 = Barely noticeable odor, 2 = Slight but clearly noticeable odor, 3 = Moderate odor, 4 = Strong odor, 5 = Extremely foul odor

Mean malodor intensity assessed at 12 hours after product use on Day 7

Time Frame: After 12 hours of product use on Day 7

Mean malodor intensity will be independently assessed by three odor trained judges 12 hours after product use on Day 7 using the following scale: 0 = No appreciable odor, 1 = Barely noticeable odor, 2 = Slight but clearly noticeable odor, 3 = Moderate odor, 4 = Strong odor, 5 = Extremely foul odor

Mean malodor intensity assessed at 12 hours after product use on Day 21

Time Frame: After 12 hours of product use on Day 21

Mean malodor intensity will be independently assessed by three odor trained judges 12 hours after product use on Day 21 using the following scale: 0 = No appreciable odor, 1 = Barely noticeable odor, 2 = Slight but clearly noticeable odor, 3 = Moderate odor, 4 = Strong odor, 5 = Extremely foul odor

Secondary Outcomes

  • Hydrogen sulfide concentration assessed at 240 minutes after product use on Day 0(After 240 minutes of product use on Day 0)
  • Methyl sulfide concentration assessed at 120 minutes after product use on Day 0(After 120 minutes of product use on Day 0)
  • Total volatile sulfur compounds (VSC) concentration assessed at 60 minutes after product use on Day 0(After 60 minutes of product use)
  • Hydrogen sulfide concentration assessed at 60 minutes after product use on Day 0(After 60 minutes of product use on Day 0)
  • Methyl mercaptan concentration assessed at 180 minutes after product use on Day 0(After 180 minutes of product use on Day 0)
  • Hydrogen sulfide concentration assessed at 120 minutes after product use on Day 0(After 120 minutes of product use on Day 0)
  • Hydrogen sulfide concentration assessed at 180 minutes after product use on Day 0(After 180 minutes of product use on Day 0)
  • Total volatile sulfur compounds (VSC) concentration assessed at 120 minutes after product use on Day 0(After 120 minutes of product use)
  • Hydrogen sulfide concentration assessed at 12 hours after product use on Day 21(After 12 hours of product use on Day 21)
  • Total volatile sulfur compounds (VSC) concentration assessed at 180 minutes after product use on Day 0(After 180 minutes of product use)
  • Total volatile sulfur compounds (VSC) concentration assessed at 240 minutes after product use on Day 0(After 240 minutes of product use)
  • Total volatile sulfur compounds (VSC) concentration assessed at 12 hours after product use on Day 7(After 12 hours of product use on Day 7)
  • Total volatile sulfur compounds (VSC) concentration assessed at 12 hours after product use on Day 21(After 12 hours of product use on Day 21)
  • Hydrogen sulfide concentration assessed at 12 hours after product use on Day 7(After 12 hours of product use on Day 7)
  • Methyl mercaptan concentration assessed at 60 minutes after product use on Day 0(After 60 minutes of product use on Day 0)
  • Methyl mercaptan concentration assessed at 12 hours after product use on Day 7(After 12 hours of product use on Day 7)
  • Methyl sulfide concentration assessed at 12 hours after product use on Day 7(After 12 hours of product use on Day 7)
  • Methyl mercaptan concentration assessed at 120 minutes after product use on Day 0(After 120 minutes of product use on Day 0)
  • Methyl mercaptan concentration assessed at 12 hours after product use on Day 21(After 12 hours of product use on Day 21)
  • Methyl sulfide concentration assessed at 12 hours after product use on Day 21(After 12 hours of product use on Day 21)
  • Methyl mercaptan concentration assessed at 240 minutes after product use on Day 0(After 240 minutes of product use on Day 0)
  • Methyl sulfide concentration assessed at 60 minutes after product use on Day 0(After 60 minutes of product use on Day 0)
  • Methyl sulfide concentration assessed at 180 minutes after product use on Day 0(After 180 minutes of product use on Day 0)
  • Methyl sulfide concentration assessed at 240 minutes after product use on Day 0(After 240 minutes of product use on Day 0)

Study Sites (1)

Loading locations...

Similar Trials